Patent · US Active

Anti CD37 antibodies

US9932399B2 · kind B2 · utility

0Cited by

7References

10Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Karl-Heinz Heider · Stockerau, AT
Eric Borges · Weitensfeld im Gurktal, AT
Elinborg Ostermann · Mauerbach, AT

Key dates

Filing date	Apr 22, 2015
Grant date	Apr 3, 2018
Priority date	—
Expiry date	Apr 22, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.